A Plus Biotechnology Co Receivables

A Plus Biotechnology Co's receivables stands at $180M as of March 2026. That compares with $170M in the prior-year period — up 6.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

A Plus Biotechnology Co reported $180M in receivables versus $170M a year earlier — a 6.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $170M in the prior-year period — up 6.2% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how A Plus Biotechnology Co's receivables evolved across reporting periods, while the comparison chart places 6918.TW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.